Project Grant 2051972

Award Date 3/1/21
Completion Date 4/30/22
Dollars Obligated $247K
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Madison, WI 53719, USA
Similar Awards
Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is focused on developing an affordable, portable virus detection platform. The $331,189 project, awarded on April 1, 2025 and running through March 31, 2028, integrates protein engineering and electrochemical biosensor technologies to create a virus detection system that can operate in resource-limited environments. The innovation lies in using stable...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...
The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to White Rock Therapeutics under the Engineering federal grant program (CFDA 47.041). The grant will support development of an ACE2 decoy as a pan-coronavirus therapeutic from January 2022 to December 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will fund initial research...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
This $249,999 National Science Foundation project grant supports the development of a bioengineered nanobarrier spray to protect against SARS-CoV-2 and other viral infections of the nasopharynx. Funded under the NSF Engineering program (CFDA 47.041), the two-year award to the University of Southern California will support computational modeling of nanobarrier delivery via nasal applicator as well as efficacy testing in a coronavirus mouse model. Specifically, the university researchers will...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This $1,000,000 Cooperative Agreement award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Akanocure Pharmaceuticals Inc.'s lead optimization of a novel, broad-spectrum antiviral and immunomodulatory agent targeting coronaviruses. The project aims to design, synthesize, and test analogs of a previously developed molecule with improved drug-like properties for oral administration. These analogs will be evaluated against several...
Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...

Nanored LLC received a $246,731 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the development of a novel SARS-CoV-2 virus-like particle optimized to deliver shRNA therapeutics from March 1, 2021 through April 30, 2022. The grant aims to prevent and treat COVID-19 infection through a delivery method utilizing virus-like particles to transport self-amplifying short hairpin RNA molecules into cells. The funding will allow Nanored LLC to advance science and engineering research leading to breakthrough technologies and solutions for pressing national challenges, consistent with the goals of the NSF TIP program.

Generated 1/6/24, 4:09 PM